Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ACP3 | P15309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23347786 | 0.84 | ALDH1A1 (0.41) | ALDH1A1ESR1NR3C2ACP3 | |
| SCHEMBL8741030 | 0.81 | CYP1A2 (0.46) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL12561078 | 0.81 | CYP1A2 (0.46) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL14215866 | 0.81 | CYP1A2 (0.49) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL18769696 | 0.80 | PPARG (0.41) | LMNAKDM4EALDH1A1ESR1NR3C2 | |
| SCHEMBL8392855 | 0.77 | SMN1; SMN2 (0.53) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL8392854 | 0.77 | SMN1; SMN2 (0.53) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL6362689 | 0.77 | CYP1A2 (0.66) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 | |
| SCHEMBL669484 | 0.75 | ALDH1A1 (0.44) | KDM4EALDH1A1ESR1NR3C2ACP3 | |
| SCHEMBL13871693 | 0.75 | CASP1 (0.41) | CYP1A2SMN1; SMN2CYP2D6PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103198-A1 | METHODS FOR TREATMENT OF COCHLEAR AND VESTIBULAR DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103198-A1 | METHODS FOR TREATMENT OF COCHLEAR AND VESTIBULAR DISORDERS | SLC26A4, C1R, C1S | CYP1A2 2905/4885SMN1; SMN2 1688/4885CYP2D6 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.